Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PROSTACOX : Metastatic Prostate Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00213694
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : March 5, 2013
Sponsor:
Information provided by:
University Hospital, Rouen

Brief Summary:
Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.

Condition or disease Intervention/treatment
Metastatic Prostate Cancer Drug: docetaxel and celecoxib

Detailed Description:
Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation

Layout table for study information
Study Type : Observational
Enrollment : 52 participants
Time Perspective: Prospective
Official Title: Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer
Study Start Date : November 2003
Study Completion Date : June 2006

Resource links provided by the National Library of Medicine






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • metastatic prostate cancer
  • ASCO progression criteria

Exclusion Criteria:

  • other prostate chemotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213694


Locations
Layout table for location information
France
Charles Nicolle, University Hospital
Rouen, France, 76031
Sponsors and Collaborators
University Hospital, Rouen
Investigators
Layout table for investigator information
Principal Investigator: Christian PFISTER, MD, PhD University Hospital, Rouen
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00213694    
Other Study ID Numbers: 2003/052/HP
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: March 5, 2013
Last Verified: March 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Celecoxib
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors